For example, our prototype targeted safeEXO-CAS sEVs displaying integrin alpha-6 (ITGA6) on their surface could be useful for the treatment of lung diseases, as our results demonstrate they can deliver functional CRISPR components to the lungs and mediate targeted efficient genome editing preferentially to targeted tissue and not the liver. This evidence concerns the gene ITGA6 and lung disorder.